Compare IDEXX Laboratories, Inc. (IDXX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs DENTSPLY SIRONA Inc — how do they compare? IDEXX Laboratories, Inc. trades at $554.16 (market cap $44.48B), while DENTSPLY SIRONA Inc trades at $13.59 (market cap $2.70B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16.5× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | XRAY | |
|---|---|---|
Market Cap | $44.48B | $2.70B |
Sector | Health | Health |
52-Week High | $766.68 | $16.85 |
52-Week Low | $520.87 | $9.64 |
Enterprise Value | $45.38B | $4.84B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
DENTSPLY SIRONA (XRAY) trades at $13.57, down 3.48% with bearish technical indicators despite a bullish moving average signal. The company shows persistent challenges with negative net income margins (-17.06%) and declining revenue trends from $3.9B in 2022 to $3.7B in 2025. Recent Q1 2026 earnings missed estimates ($0.27 vs. $0.28 expected), continuing a pattern of underperformance. Analyst sentiment remains cautious with a 'Hold' consensus rating and $13.33 price target, slightly below current levels.
The stock faces significant fundamental headwinds including consecutive earnings misses, declining profitability, and rising debt-to-asset ratio (42.88% in 2025). While technical indicators show some bullish momentum, the weak financial performance and negative investor sentiment suggest limited near-term upside potential. The appointment of a new CFO and distribution expansions provide some operational optimism, but execution risks remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
